The Development, Validation, and Utility of the Diabetes Prevention Trial-Type 1 Risk Score (DPTRS)

Current Diabetes Reports

Volumn 15, Issue 8, 2015, Pages

  Sosenko, Jay M ^a   Skyler, Jay S ^a   Palmer, Jerry P ^b  

^a UNIVERSITY OF MIAMI   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

C peptide; Diagnosis; Glucose; Prediction; Type 1 diabetes

Indexed keywords

AUTOANTIBODY; C PEPTIDE; GLUCOSE; GLUCOSE BLOOD LEVEL;

AGE; ASSESSMENT OF HUMANS; BODY MASS; CLINICAL TRIAL (TOPIC); DIABETES PREVENTION TRIAL TYPE 1 RISK SCORE; DYSGLYCEMIA; GLUCOSE BLOOD LEVEL; HEALTH CARE UTILIZATION; HIGH RISK POPULATION; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; LOW RISK POPULATION; ORAL GLUCOSE TOLERANCE TEST; PATIENT IDENTIFICATION; PATIENT SELECTION; PREDICTION; PREVENTION STUDY; PROGRAM DEVELOPMENT; REVIEW; RISK ASSESSMENT; VALIDATION STUDY; ANALYSIS; BLOOD; DIABETES MELLITUS, TYPE 1; METABOLISM; RISK FACTOR;

AUTOANTIBODIES; BLOOD GLUCOSE; C-PEPTIDE; DIABETES MELLITUS, TYPE 1; HUMANS; PREDIABETIC STATE; RISK FACTORS;

EID: 84935915908     PISSN: 15344827     EISSN: 15390829     Source Type: Journal    
DOI: 10.1007/s11892-015-0626-1     Document Type: Review

References (16)

1. Gale EA, Bingley PJ, Emmett CL, Collier T, the European Nicotinamide Diabetes Intervention Trial (ENDIT) Group. European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1. Lancet. 2004;363:925–31.
2. Diabetes Prevention Trial-Type 1 Diabetes Study Group. Effects of oral insulin in relatives of patients with type 1 diabetes. Diabetes Care. 2005;28:1068–76. This was one of the prevention trials from which the DPTRS was derived.
3. Diabetes Prevention Trial-Type 1 Diabetes Study Group. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med. 2002;346:1685–91. This was one of the prevention trials from which the DPTRS was derived.
4. Bottazzo JF, Mann JI, Thorogood M, Baum JD, Doniach D. Autoimmunity in juvenile diabetics and their families. Br Med J. 1978;2(6131):165–8.
5. Cudworth AG, Woodrow JC. Evidence of HL-A linked genes in “juvenile” diabetes mellitus. Br Med J. 1975;3(5976):133–5.
6. Vardi P, Crisa L, Jackson RA. Predictive value of intravenous glucose tolerance test insulin secretion less than or greater than the first percentile in islet cell antibody positive relatives of type 1 (insulin-dependent) diabetic patients. Diabetologia. 1991;34:93–102.
7. Rosenbloom AL, Hunt SS, Rosenbloom EK, Maclaren NK. Ten-year prognosis of impaired glucose tolerance in siblings of patients with insulin-dependent diabetes. Diabetes. 1982;31:385–7.
8. Ziegler AG, Rewers M, Simell O, Simell T, Lempainen J, Steck A, et al. Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA. 2013;309:2473–9.
9. Orban T, Sosenko JM, Cuthbertson D, Krischer JP, Skyler JS, Jackson R, et al. Pancreatic islet autoantibodies as predictors of type 1 diabetes in the Diabetes Prevention Trial-Type 1 (DPT-1). Diabetes Care. 2009;32:2269–74.
10. Sosenko J, Palmer JP, Greenbaum CJ, Mahon J, Cowie C, Krischer JP, et al. Increasing the accuracy of oral glucose tolerance testing and extending its application to individuals with normal glucose tolerance for the prediction of type 1 diabetes. Diabetes Care. 2007;30:38–42.
11. Sosenko JM, Krischer JP, Palmer JP, Mahon J, Cowie C, Greenbaum CJ, et al. A risk score for type 1 diabetes derived from autoantibody positive participants in The Diabetes Prevention Trial-Type 1. Diabetes Care. 2008;31:528–33. This is the first article to describe the development of the DPTRS.
12. Sosenko JM, Skyler JS, Mahon J, Krischer JP, Beam CA, Boulware DC, et al. Validation of the Diabetes Prevention Trial-Type 1 Risk Score (DPTRS) in the TrialNet Natural History Study. Diabetes Care. 2011;34:1785–7.
13. Sosenko JM, Skyler JS, Mahon J, Krischer JP, Greenbaum CJ, Rafkin LE, et al. The use of the Diabetes Prevention Trial-Type 1 Risk Score (DPTRS) for improving the accuracy of the risk classification of type 1 diabetes. Diabetes Care. 2014;37:979–84.
14. Sosenko JM, Skyler JS, Mahon J, Krischer JP, Beam CA, Boulware DC, et al. The application of the type 1 diabetes risk score for identifying a preclinical state of type 1 diabetes. Diabetes Care. 2012;35:1552–5.
15. Ilonen J, Hammais A, Laine A, Lempainen J, Vaarala O, Veijola R, et al. Patterns of β-cell autoantibody appearance and genetic associations during the first years of life. Diabetes. 2013;62:3636–40.
16. Sosenko JM, Skyler JS, Palmer JP, Krischer JP, Yu L, Mahon J, et al. The prediction of type 1 diabetes by multiple autoantibody levels and their incorporation into an autoantibody risk score in relatives of type 1 diabetic patients. Diabetes Care. 2013;36:2615–20.